Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 540-544, 2005; 10.1373/clinchem.2004.037804
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petersen, J. R.
Right arrow Articles by Shattuck, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petersen, J. R.
Right arrow Articles by Shattuck, K. E.
Related Collections
Right arrow Pediatric Clinical Chemistry
Right arrow Evidence Based Laboratory Medicine and Test Utilization
(Clinical Chemistry. 2005;51:540-544.)
© 2005 American Association for Clinical Chemistry, Inc.


Evidence-based Laboratory Medicine and Test Utilization

Association of Transcutaneous Bilirubin Testing in Hospital with Decreased Readmission Rate for Hyperbilirubinemia

John R. Petersen1,a, Anthony O. Okorodudu1, Amin A. Mohammad1, Amarasiri Fernando1,1 and Karen E. Shattuck2

Departments of1 Pathology and2 Pediatrics, University of Texas Medical Branch, Galveston, TX.

aAddress correspondence to this author at: Department of Pathology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-0551. Fax 409-772-9231; e-mail jrpeters{at}utmb.edu.

Background: Newborns are being discharged from hospitals within 1–2 days of birth, before hyperbilirubinemia usually becomes clinically evident. We investigated the use of transcutaneous bilirubin (TcB) before discharge to determine whether it affects the use of laboratory bilirubin testing or decreases the number of neonates readmitted for hyperbilirubinemia within 7 days of initial discharge.

Methods: We retrospectively searched a clinical laboratory and hospital database to determine the number of births, newborn readmission rates for hyperbilirubinemia, length of stay, and the number of bilirubin measurements in the clinical laboratory ordered for all babies in the newborn unit at the University of Texas Medical Branch from August 2002 to March 2003 (before TcB testing) and from May 2003 to December 2003 (after TcB).

Results: Between August 2002 and December 2003, 8974 newborns (both vaginal and cesarean births) were admitted to the newborn nursery. Babies who did not fit the diagnosis-related group criteria of "normal newborn" were removed, leaving 6933 babies who were included in the study. April was considered a transition month and was not included in the study, leaving 6603 newborns to be included. Of these, 446 (6.8%) required phototherapy for treatment of hyperbilirubinemia before initial discharge. For the 8 months before and 8 months after initiation of TcB testing, the number of laboratory bilirubin measurements ordered per newborn did not change, nor did the mean (SD) length of stay for normal newborns [2.15 (1.1) days vs 2.12 (1.1) days; P = 0.53], nor days of treatment with phototherapy before discharge [2.9 (1.3) days vs 2.9 (1.3) days; P = 0.67]. By contrast, the number of readmissions per 1000 newborns per month for clinically significant hyperbilirubinemia decreased significantly (Wilcoxon rank-sums two-sample test, P = 0.044), from 4.5 (2.4) to 1.8 (1.7) after TcB testing was initiated.

Conclusion: Access to TcB testing is associated with a reduction in the hospital readmission rate for hyperbilirubinemia within 7 days of the initial discharge.




The following articles in journals at HighWire Press have cited this article:


Home page
Ann Clin BiochemHome page
J. M Kirk
Neonatal jaundice: a critical review of the role and practice of bilirubin analysis
Ann Clin Biochem, September 1, 2008; 45(5): 452 - 462.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
H T Ho, T K Ng, K C Tsui, and Y C Lo
Evaluation of a new transcutaneous bilirubinometer in Chinese newborns
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2006; 91(6): F434 - F438.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
D. K. Stevenson, R. J. Wong, and H. J. Vreman
Reduction in Hospital Readmission Rates for Hyperbilirubinemia Is Associated with Use of Transcutaneous Bilirubin Measurements
Clin. Chem., March 1, 2005; 51(3): 481 - 482.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.